Skip to main content
Fig. 3 | BMC Research Notes

Fig. 3

From: Treatment potential of pathogen-reactive antibodies sequentially purified from pooled human immunoglobulin

Fig. 3

Pathogen-reactive E-IVIG can be sequentially purified from a single vial of IVIG without appreciable loss in opsonophagocytic activity. Black bars show activity of E-IVIG (primary purification from IVIG); grey bars show activity of sequentially-purified E-IVIG, (secondarily-purified from flow through fraction of an earlier, primary E-IVIG purification); white bars show activity of commercial IVIG. All immunoglobulin preparations were used at 25 µg/ml. a Anti S. pyogenes E-IVIG activity against H364. Sequentially purified E-IVIG was prepared from flow-through of primary S. aureus E-IVIG purification b Anti S. aureus E-IVIG activity against USA300. Sequentially purified E-IVIG was prepared from flow-through of primary S. pyogenes E-IVIG purification. c Anti-VRE E-IVIG activity against H1548. Sequentially purified E-IVIG was prepared from flow through obtained following purification of S. pyogenes E-IVIG and then S. aureus E-IVIG. Neutrophil uptake of bacteria in the absence of any IVIG is shown by the horizontal dotted line (PBS only). Results from three different neutrophil donors are displayed as the percentage of neutrophils containing Oregon green 488-X SE labelled bacteria (Mean ± SD)

Back to article page